ABSTRACT
Eight manufacturing facilities participating in the National Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed and implemented a harmonized process for the manufacture of allogeneic purified human pancreatic islet (PHPI) product evaluated in a phase 3 trial in subjects with type 1 diabetes. Manufacturing was controlled by a common master production batch record, standard operating procedures that included acceptance criteria for deceased donor organ pancreata and critical raw materials, PHPI product specifications, certificate of analysis, and test methods. The process was compliant with Current Good Manufacturing Practices and Current Good Tissue Practices. This report describes the manufacturing process for 75 PHPI clinical lots and summarizes the results, including lot release. The results demonstrate the feasibility of implementing a harmonized process at multiple facilities for the manufacture of a complex cellular product. The quality systems and regulatory and operational strategies developed by the CIT Consortium yielded product lots that met the prespecified characteristics of safety, purity, potency, and identity and were successfully transplanted into 48 subjects. No adverse events attributable to the product and no cases of primary nonfunction were observed.
Subject(s)
Islets of Langerhans Transplantation/methods , Adolescent , Adult , Aged , Female , Humans , Islets of Langerhans , Islets of Langerhans Transplantation/economics , Male , Middle Aged , National Institutes of Health (U.S.) , United States , Young AdultSubject(s)
Culture Techniques/methods , Islets of Langerhans/cytology , Tissue and Organ Harvesting/methods , Adenosine/chemistry , Allopurinol/chemistry , Glutathione/chemistry , Humans , Insulin/chemistry , Islets of Langerhans Transplantation/methods , Organ Preservation Solutions/chemistry , Raffinose/chemistry , Retrospective Studies , Time FactorsSubject(s)
Islets of Langerhans Transplantation/methods , Islets of Langerhans/cytology , Pancreas/enzymology , Absorption , Arginine/analogs & derivatives , Arginine/chemistry , Cell Culture Techniques/economics , Cell Culture Techniques/methods , Collagenases/metabolism , Cost-Benefit Analysis , Humans , Islets of Langerhans Transplantation/economics , Middle Aged , Pancreas/metabolism , Perfusion , Time Factors , Treatment Outcome , Trypsin/metabolismABSTRACT
Culture of human islets before clinical transplantation or distribution for research purposes is standard practice. At the time the Edmonton protocol was introduced, clinical islet manufacturing did not include culture, and human serum albumin (HSA), instead of fetal bovine serum (FBS), was used during other steps of the process to avoid the introduction of xenogeneic material. When culture was subsequently introduced, HSA was also used for medium supplementation instead of FBS, which was typically used for research islet culture. The use of HSA as culture supplement was not evaluated before this implementation. We performed a retrospective analysis of 103 high-purity islet preparations (76 research preparations, all with FBS culture supplementation, and 27 clinical preparations, all with HSA supplementation) for oxygen consumption rate per DNA content (OCR/DNA; a measure of viability) and diabetes reversal rate in diabetic nude mice (a measure of potency). After 2-day culture, research preparations exhibited an average OCR/DNA 51% higher (p < 0.001) and an average diabetes reversal rate 54% higher (p < 0.05) than clinical preparations, despite 87% of the research islet preparations having been derived from research-grade pancreata that are considered of lower quality. In a prospective paired study on islets from eight research preparations, OCR/DNA was, on average, 27% higher with FBS supplementation than that with HSA supplementation (p < 0.05). We conclude that the quality of clinical islet preparations can be improved when culture is performed in media supplemented with serum instead of albumin.
Subject(s)
Culture Media , Islets of Langerhans/drug effects , Serum Albumin/pharmacology , Serum , Animals , Cattle , Cell Culture Techniques , Cells, Cultured , Culture Media/pharmacology , Diabetes Mellitus, Experimental/mortality , Diabetes Mellitus, Experimental/surgery , Humans , Islets of Langerhans/cytology , Islets of Langerhans Transplantation , Kaplan-Meier Estimate , Mice , Mice, Nude , Oxygen Consumption , Retrospective Studies , Transplantation, HeterologousABSTRACT
BACKGROUND: The ability to predict clinical function of a specific islet batch released for clinical transplantation using standardized variables remains an elusive goal. METHODS: Analysis of 10 donor, 7 islet isolation, 3 quality control, and 6 recipient variables was undertaken in 110 islet-after-kidney transplants and correlated to the pre- to 28-day posttransplant change in C-peptide to glucose and creatinine ratio (ΔCP/GCr). RESULTS: Univariate analysis yielded islet volume transplanted (Spearman r=0.360, P<0.001) and increment of insulin secretion (r=0.377, P<0.001) as variables positively associated to ΔCP/GCr. A negative association to ΔCP/GCr was cold ischemia time (r=-0.330, P<0.001). A linear, backward-selection multiple regression was used to obtain a model for the transplanted functional islet mass (TFIM). The TFIM model, composed of islet volume transplanted, increment of insulin secretion, cold ischemia time, and exocrine tissue volume transplanted, accounted for 43% of the variance of the clinical outcome in the islet-after-kidney data set. CONCLUSION: The TFIM provides a straightforward and potent tool to guide the decision to use a specific islet preparation for clinical transplantation.
Subject(s)
Graft Survival/physiology , Islets of Langerhans Transplantation/physiology , Islets of Langerhans Transplantation/standards , Islets of Langerhans/physiology , Kidney Transplantation/physiology , Tissue Donors , Transplantation/physiology , Adult , Age Factors , Aged , Blood Glucose/metabolism , C-Peptide/blood , Cells, Cultured , Cold Ischemia , Creatinine/blood , Diabetes Mellitus, Type 1/surgery , Diabetic Nephropathies/surgery , Female , Humans , Insulin , Islets of Langerhans/anatomy & histology , Male , Middle Aged , Models, Biological , Organ Size , Quality Control , Retrospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: Accurate islet quantification has proven difficult to standardize in a good manufacturing practices (GMP) approved manner. METHODS: The influence of assessment variables from both manual and computer-assisted digital image analysis (DIA) methods were compared using calibrated, standardized microspheres or islets alone. Additionally, a mixture of microspheres and exocrine tissue was used to evaluate the variability of both the current, internationally recognized, manual method and a novel GMP-friendly purity- and volume-based method (PV) evaluated by DIA in a semiclosed, culture bag system. RESULTS: Computer-assisted DIA recorded known microsphere size distribution and quantities accurately. By using DIA to evaluate islets, the interindividual manually evaluated percent coefficients of variation (CV%; n=14) were reduced by almost half for both islet equivalents (IEs; 31% vs. 17%, P=0.002) and purity (20% vs. 13%, P=0.033). The microsphere pool mixed with exocrine tissue did not differ from expected IE with either method. However, manual IE resulted in a total CV% of 44.3% and a range spanning 258 k IE, whereas PV resulted in CV% of 10.7% and range of 60 k IE. Purity CV% for each method were similar approximating 10.5% and differed from expected by +7% for the manual method and +3% for PV. CONCLUSION: The variability of standard counting methods for islet samples and clinical quantities of microspheres mixed with exocrine tissue were reduced with DIA. They were reduced even further by use of a semiclosed bag system compared with standard manual counting, thereby facilitating the standardization of islet evaluation according to GMP standards.